Study Highlights Long-Term Effectiveness of FDA-Approved Pralsetinib in Treating RET Fusion-Positive NSCLC

A recent study conducted by researchers at the Mass General Brigham Cancer Institute has highlighted the long-term effectiveness of pralsetinib, a targeted therapy approved by the U.S. Food and Drug Administration (FDA), in treating non-small cell lung cancers (NSCLCs) associated with RET gene fusions. RET fusions are a rare genetic alteration found in a subset of NSCLC cases, and this research provides new insights into treatment outcomes for patients with these mutations.

The study focused on evaluating pralsetinib’s impact on survival rates among patients diagnosed with RET fusion-positive NSCLC. Researchers analyzed data to assess how this targeted therapy influences long-term survival compared to other treatment options. The findings underscore pralsetinib’s potential as an effective therapeutic approach for addressing these specific genetic alterations in lung cancer patients. This development adds to ongoing efforts to improve personalized medicine strategies for individuals with rare cancer-related genetic mutations.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 1, 2026

Author

GOAI